Jennifer Tsai

Experience

• 

  National Taiwan University

  Jun 1995 - Jul 1996

  Reseach Assistant
• 

  Ren-Ji Pharmaceuticals, Inc.

  Jan 1998 - Jan 1999

  Deputy Manager, President Office
• 

  Sunsino Ventures Group

  Jan 1999 - Jan 2002

  Investment Specialist, Investment Div.
• 

  United Biomedical, Inc. (UBI)

  Jan 1999 - Jan 1999

  Marketing Specialist, Sales & Marketing Div.

  United Biomendical, Inc.- Asia

• 

  China Development Industrial Bank

  Jan 2002 - Jan 2003

  Deputy Manager, Overseas Business Div., Direct Investment Div.

  CDIB Capital Group － Focusing on Core Businesses of Private Equity Investment & Venture Capital Asset Management CDIB Capital Group, formerly China Development Industrial Bank, was the first private development-oriented financial institution in Taiwan. It has long worked in close partnership with the government to play a pivotal role in supporting Taiwan's industrial development and economic growth through pioneering the local venture capital and investment banking markets. Today, CDIB Capital Group remains the predominant leader in venture capital business in Taiwan, with a market share of over 30%. In recent years, CDIB Capital Group has been proactively engaged in the administration’s call for a structural upgrade in the financial sector by focusing on raising and managing private equity funds and venture capital assets, and is backed by a wealth of experience supporting Taiwan’s industrial development. Looking forward, CDIB Capital Group aims to become one of the best private equity/venture capital asset management companies in the Asia-Pacific region. Show less

• 

  Development Center for Biotechnology

  Jan 2004 - Nov 2009

  Director, Business Development

  DCB, the Development Center for Biotechnology, was founded in 1984 based on governmental funds and private donations.DCB's mission is to facilitate the development of Taiwan's biotechnology industry by building the infrastructures, developing key biotechnologies, and training and recruiting professional workforces, in coordination with industrial, governmental, academic, and research institutions.DCB, as aiming to act as the “best partner for biotech industry,” plays the role as a “second runner” of value-adding and incubation in the value chain of Taiwan’s biotech-pharma industry. It continues the new drug discovery results of the first-runner research and academic institutions and introduces innovative technology or lead compounds from foreign entities. Via pre-clinical development and value-adding, those achievements are to be transferred to the third-runner biotech-pharma companies where the R&D results are directed to commercialization. By suitable business models such as technology introduction, strategic alliance, research collaboration, OEM services, technology transfer, or spinning off start-ups, DCB dedicates to efficiently utilizing the biotech research resources integratively, to accelerating the increase of Taiwan’s biotech-pharma industrial values, to cooperatively creating the new value of biotech-pharma industry, and to moving forward to global market. Show less

• 

  Academia-Industry Bridging Program for National Science and Technology Projects

  Nov 2006 - Nov 2009

  Associate Instructor

  Mission- Promoting the Transfer of Innovations from National Research Programs for Industry Use and Public Benefit- Providing Rewarding Incentives to Inventors to Encourage Technologic Innovations on Concrete Academic BasisWhat We Do Protecting and Managing Intellectual Property Rights  Evaluating and Assessing the Market Potential & Patents of the Inventions Backing Patent Filing and Prosecution Marketing & Promoting Awareness of Intellectual Property and Entrepreneurialism  Handling the Process of Licensing & Transferring Intellectual Property Monitoring Licensees Performance Managing & Disbursing Licensing Revenues to IPR holdersAboutAcademia-Industry Bridging Program (AIBP) manages the intellectual properties (IP) developed by national research programs in biotechnology & pharmaceuticals (the NSTPBP), genomic medicine (the NRPGM) and 3 major medical centers in Taiwan. Founded in 2006 by National Science and Technology Programs in Taiwan, AIBP handles both patentable inventions and biomaterials. Each licensing officer has technical trainings, most possess interdisciplinary backgrounds (law, finance, or IP) and spent dozen years in patent review, product development, project management and/or business development. AIBP manages invention disclosures from beginning to end, including evaluating the disclosures, assessing market and IP, backing patent filing, marketing, negotiating, and monitoring licensee performance. AIBP proactively seeks to foster the development of medical inventions through technology licensing and cooperative research between inventors and industry. Our charter is to help turn the scientific results into tangible products that address public benefit. Show less

• 

  YFY Biotech Management Company / Taiwan Global BioFund

  Nov 2009 - now

  BOD member, Chief Operating Officer and Executive Vice President

  YFY Biotech Management Company / Taiwan Global BioFund1. Venture Capital Investment and Management2. Technology Incubation and Commercialization3. Financial Advisory, Business Management and Company GovernanceYFY Biotech Management is the healthcare-focused venture arm of YFY, Inc. (1907.TWO). Established in Nov 2003, YFY Biotech Management is among the Taiwan leaders in healthcare-focused incubating and investment.YFY Biotech Management focuses on pharm, med-tech, diagnostic and bio-tech innovations in seed stage, start-up, and developing stage.YFY Biotech Management advises Taiwan Global Biofund (TGB) as well as SME fund with approximately USD 100-millions under management.The experienced professionals of YFY Biotech Management has earned the reputation as Taiwan leading biotech venture, as more and more of the portfolio companies have stay reaching remarkable milestones and are successfully listed in Taiwan’s vibrant stock exchange. Show less

• 

  Medigreen Biotechnology Corp.

  Jun 2010 - Jan 2013

  BOD Member

  Medigreen Biotechnology Corporation, founded on April 10th, 2002, is focusing on the development of botanical new drugs and is established by domestic and overseas outstanding enterprises and entrepreneurs, in accordance with the government’s promotion policy, to develop the Chinese Traditional Medicine industry. The major stockholders of Medigreen include Medigen Biotechnology Corp., SunTen Phytotech Co., Ltd. and YFY Biotech Management Company

• 

  MiCareo, Inc.

  Sept 2015 - now

  BOD member

  MiCareo is a biotechnology company that develop innovative tools for rare cell analysis and personalized medicine, which particularly be apllied on cancer prognisis, treatment and management. Based on its proprietary & patented microfluidic lab-on-chip platform, MiCareo develops and offers instrument system, MiSelct Rare System, for isolation, identification and analysis of Circulating Tumor Cells (CTCs) and immune cells from whole blood.

• 

  Somnics, Inc.

  May 2016 - Jan 2019

  BOD member

  Somnics focus on developing innovative technologies for the treatment of Obstructive Sleep Apnea (OSA), and provides patient-centered and user friendly solutions for comfort and restful sleep. iNAP® sleep therapy system provides a simple, comfortable and discreet way to treat OSA (Obstructive Sleep Apnea) and allow more patients with OSA to breath naturally wherever they are.Certificates •ISO 13485:2003, EN ISO 13485:2012 & ISO 9001:2008•EC Certificate onMDD (93/42/EEC)•GMP Certificate Show less

• 

  TaiGen Biotechnology

  Nov 2018 - now

  Supervisor

  TaiGen Biotechnology Co., Ltd. (Ticker: 4157.TWO) is a research-based and product-driven pharmaceutical company engaging in the development of novel therapeutics for infectious diseases, cancer and diabetes-related complications. TaiGen has a wholly-owned Beijing subsidiary with a proven capacity to conduct clinical trials and related registrations. TaiGen's current pipeline includes "first-in-class" and "best-in-class" products with worldwide IP rights.